Industry Focus
Industry Focus
The Motley Fool
Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis
24 minutes Posted Aug 14, 2019 at 12:30 pm.
0:00
24:14
Download MP3
Show notes

The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.

Check out more of our content here: